Endoscopic ultrasound-guided celiac plexus neurolysis in pancreatic cancer: A prospective pilot study of safety using 10 ml versus 20 ml alcohol

Julia K. Leblanc, Susan Rawl, Michelle Juan, Cynthia Johnson, Kurt Kroenke, Lee McHenry, Stuart Sherman, Kathy McGreevy, Mohammad Al-Haddad, John DeWitt

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background. The dose of alcohol used in EUS-CPN is not standardized. The objective was to compare the safety of 20 mL alcohol versus 10 mL alcohol during EUS-CPN for patients with pancreatic cancer-related pain. Methods. 20 patients were selected to receive 10 mL or 20 mL of alcohol during EUS-CPN. Followup was done at baseline, 24 hours, and weekly. Health-related quality of life (HRQoL) was assessed at baseline, week 2, week 4, and every 4 weeks thereafter until pain returned. Results. There were no major complications in both groups. Minor self-limited adverse effects were seen in 6 (30%) subjects and included lightheadedness in 1 (5%), transient diarrhea in 2 (10%), and transient nausea and vomiting in 3. Pain relief was similar in both groups: 80% in the 10 mL group and 100% in the 20 mL group (P=0.21). The mean (± SD) duration of pain relief in the 10 mL and 20 mL groups was 7.9±10.8 and 8.4±9.2 weeks, respectively. 30% of patients in each group had complete pain relief. Conclusions. EUS-CPN using 20 mL of alcohol is safe. Similar clinical outcomes were seen in both groups. Further investigations to confirm these findings are warranted.

Original languageEnglish
Article number327036
JournalDiagnostic and Therapeutic Endoscopy
Volume2013
DOIs
StatePublished - 2013

Fingerprint

Celiac Plexus
Pancreatic Neoplasms
Alcohols
Prospective Studies
Safety
Pain
Dizziness
Nausea
Vomiting
Diarrhea
Quality of Life

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Endoscopic ultrasound-guided celiac plexus neurolysis in pancreatic cancer : A prospective pilot study of safety using 10 ml versus 20 ml alcohol. / Leblanc, Julia K.; Rawl, Susan; Juan, Michelle; Johnson, Cynthia; Kroenke, Kurt; McHenry, Lee; Sherman, Stuart; McGreevy, Kathy; Al-Haddad, Mohammad; DeWitt, John.

In: Diagnostic and Therapeutic Endoscopy, Vol. 2013, 327036, 2013.

Research output: Contribution to journalArticle

@article{b19dbb6014044e90a7ddb0d3a02577f5,
title = "Endoscopic ultrasound-guided celiac plexus neurolysis in pancreatic cancer: A prospective pilot study of safety using 10 ml versus 20 ml alcohol",
abstract = "Background. The dose of alcohol used in EUS-CPN is not standardized. The objective was to compare the safety of 20 mL alcohol versus 10 mL alcohol during EUS-CPN for patients with pancreatic cancer-related pain. Methods. 20 patients were selected to receive 10 mL or 20 mL of alcohol during EUS-CPN. Followup was done at baseline, 24 hours, and weekly. Health-related quality of life (HRQoL) was assessed at baseline, week 2, week 4, and every 4 weeks thereafter until pain returned. Results. There were no major complications in both groups. Minor self-limited adverse effects were seen in 6 (30{\%}) subjects and included lightheadedness in 1 (5{\%}), transient diarrhea in 2 (10{\%}), and transient nausea and vomiting in 3. Pain relief was similar in both groups: 80{\%} in the 10 mL group and 100{\%} in the 20 mL group (P=0.21). The mean (± SD) duration of pain relief in the 10 mL and 20 mL groups was 7.9±10.8 and 8.4±9.2 weeks, respectively. 30{\%} of patients in each group had complete pain relief. Conclusions. EUS-CPN using 20 mL of alcohol is safe. Similar clinical outcomes were seen in both groups. Further investigations to confirm these findings are warranted.",
author = "Leblanc, {Julia K.} and Susan Rawl and Michelle Juan and Cynthia Johnson and Kurt Kroenke and Lee McHenry and Stuart Sherman and Kathy McGreevy and Mohammad Al-Haddad and John DeWitt",
year = "2013",
doi = "10.1155/2013/327036",
language = "English",
volume = "2013",
journal = "Diagnostic and Therapeutic Endoscopy",
issn = "1070-3608",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Endoscopic ultrasound-guided celiac plexus neurolysis in pancreatic cancer

T2 - A prospective pilot study of safety using 10 ml versus 20 ml alcohol

AU - Leblanc, Julia K.

AU - Rawl, Susan

AU - Juan, Michelle

AU - Johnson, Cynthia

AU - Kroenke, Kurt

AU - McHenry, Lee

AU - Sherman, Stuart

AU - McGreevy, Kathy

AU - Al-Haddad, Mohammad

AU - DeWitt, John

PY - 2013

Y1 - 2013

N2 - Background. The dose of alcohol used in EUS-CPN is not standardized. The objective was to compare the safety of 20 mL alcohol versus 10 mL alcohol during EUS-CPN for patients with pancreatic cancer-related pain. Methods. 20 patients were selected to receive 10 mL or 20 mL of alcohol during EUS-CPN. Followup was done at baseline, 24 hours, and weekly. Health-related quality of life (HRQoL) was assessed at baseline, week 2, week 4, and every 4 weeks thereafter until pain returned. Results. There were no major complications in both groups. Minor self-limited adverse effects were seen in 6 (30%) subjects and included lightheadedness in 1 (5%), transient diarrhea in 2 (10%), and transient nausea and vomiting in 3. Pain relief was similar in both groups: 80% in the 10 mL group and 100% in the 20 mL group (P=0.21). The mean (± SD) duration of pain relief in the 10 mL and 20 mL groups was 7.9±10.8 and 8.4±9.2 weeks, respectively. 30% of patients in each group had complete pain relief. Conclusions. EUS-CPN using 20 mL of alcohol is safe. Similar clinical outcomes were seen in both groups. Further investigations to confirm these findings are warranted.

AB - Background. The dose of alcohol used in EUS-CPN is not standardized. The objective was to compare the safety of 20 mL alcohol versus 10 mL alcohol during EUS-CPN for patients with pancreatic cancer-related pain. Methods. 20 patients were selected to receive 10 mL or 20 mL of alcohol during EUS-CPN. Followup was done at baseline, 24 hours, and weekly. Health-related quality of life (HRQoL) was assessed at baseline, week 2, week 4, and every 4 weeks thereafter until pain returned. Results. There were no major complications in both groups. Minor self-limited adverse effects were seen in 6 (30%) subjects and included lightheadedness in 1 (5%), transient diarrhea in 2 (10%), and transient nausea and vomiting in 3. Pain relief was similar in both groups: 80% in the 10 mL group and 100% in the 20 mL group (P=0.21). The mean (± SD) duration of pain relief in the 10 mL and 20 mL groups was 7.9±10.8 and 8.4±9.2 weeks, respectively. 30% of patients in each group had complete pain relief. Conclusions. EUS-CPN using 20 mL of alcohol is safe. Similar clinical outcomes were seen in both groups. Further investigations to confirm these findings are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84873362173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873362173&partnerID=8YFLogxK

U2 - 10.1155/2013/327036

DO - 10.1155/2013/327036

M3 - Article

C2 - 23365492

AN - SCOPUS:84873362173

VL - 2013

JO - Diagnostic and Therapeutic Endoscopy

JF - Diagnostic and Therapeutic Endoscopy

SN - 1070-3608

M1 - 327036

ER -